Sign in
Not yet taking people in AustriaPhase 1

Tests NTR-641 in healthy adults and people with acute ischemic stroke

Tests NTR-641 for safety in healthy adults and adults with acute ischemic stroke.

Key facts

Who runs it
Neutrolis Inc.
Where
Vienna, AustriaSee the 2 sites
Registry title
A randomized, placebo-controlled, double-blind, single-ascending-dose, Phase 1a/b study to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous NTR-641 in healthy adults and patients with acute ischemic stroke
Status
Not yet recruiting
Phase
Phase 1
People taking part
72 people, planned
Started
14 Oct 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
21 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults and adults with acute ischemic stroke to test the safety of a drug called NTR-641 given into a vein.

Age
18 years or older
Sex
All sexes can join
Disease stage
Acute ischemic stroke (for the patient part); healthy adults are also included

Where in Austria

  • Krankenhaus Der Barmherzigen Brueder WienVienna, AustriaNot yet recruiting
  • Medical University of ViennaVienna, AustriaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests NTR-641 in healthy adults and people with acute ischemic strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 July 2025